$4.78
2.25% today
Nasdaq, Feb 05, 03:30 pm CET
ISIN
US30049G1040
Symbol
EVOK
Sector
Industry

Evoke Pharma, Inc. Stock price

$4.89
+0.29 6.30% 1M
-0.14 2.78% 6M
+0.47 10.63% YTD
-3.27 40.07% 1Y
-67.12 93.21% 3Y
-205.35 97.67% 5Y
-751.11 99.35% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.11 2.30%
ISIN
US30049G1040
Symbol
EVOK
Sector
Industry

Key metrics

Market capitalization $7.27m
Enterprise Value $930.00k
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.11
P/S ratio (TTM) P/S ratio 0.84
P/B ratio (TTM) P/B ratio 1.00
Revenue growth (TTM) Revenue growth 100.35%
Revenue (TTM) Revenue $8.62m
EBIT (operating result TTM) EBIT $-5.90m
Free Cash Flow (TTM) Free Cash Flow $-5.32m
Cash position $11.34m
EPS (TTM) EPS $-11.09
P/S forward 0.73
EV/Sales forward 0.09
Short interest 2.62%
Show more

Is Evoke Pharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Evoke Pharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Evoke Pharma, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Evoke Pharma, Inc.:

Buy
100%

Financial data from Evoke Pharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
8.62 8.62
100% 100%
100%
- Direct Costs 0.30 0.30
9% 9%
3%
8.32 8.32
110% 110%
97%
- Selling and Administrative Expenses 14 14
29% 29%
165%
- Research and Development Expense 0.04 0.04
79% 79%
0%
-5.90 -5.90
19% 19%
-68%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -5.90 -5.90
19% 19%
-68%
Net Profit -6.15 -6.15
19% 19%
-71%

In millions USD.

Don't miss a Thing! We will send you all news about Evoke Pharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evoke Pharma, Inc. Stock News

Positive
Proactive Investors
19 days ago
Expect shares in William Hill owner Evoke PLC to get off to a strong start when the market opens. That's because the bookmaker said full-year earnings for 2024 will surpass market expectations, with strong double-digit revenue growth in the fourth quarter driven by its online business.
Neutral
GlobeNewsWire
about 2 months ago
FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025 Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and related costs compared to oral metoclopramide SOLANA BEACH, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused pri...
Neutral
GlobeNewsWire
2 months ago
SOLANA BEACH, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it has received notices of allowance for two U.S. patent applications by the United States Patent and Trademark Office, furth...
More Evoke Pharma, Inc. News

Company Profile

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Head office United States
CEO Matthew D'Onofrio
Employees 4
Founded 2007
Website www.evokepharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today